Because of the overrepresentation of patients with diabetic disease in the ACE-inhibitor group, and the apparently reduced AAA progression in patients with diabetic disease on aneurysm progression we repeated the analysis after exclusion of patients with diabetic disease. Here, ACE is linked to triple-A syndrome.